Table 1.
Clinical and angiographic characteristics.
| All patients |
CMR population |
|||||
|---|---|---|---|---|---|---|
| <60 years (n = 753) ≥ 60 years (n = 850) P | <60 years (n = 455) ≥ 60 years (n = 352) P | |||||
| Age, years | 51 (6) | 71 (7) | <0.001 | 51 (6) | 69 (6) | <0.001 |
| Male | 613 (81%) | 612 (72%) | <0.001 | 377 (83%) | 264 (75%) | 0.006 |
| BMI | 27 (25–29) | 26 (24–29) | <0.001 | 27 (25–29) | 26 (24–29) | 0.001 |
| Risk factors | ||||||
| Diabetes | 76 (10%) | 81 (10%) | 0.70 | 36 (8%) | 31 (9%) | 0.65 |
| Hypertension | 234 (31%) | 422 (50%) | <0.001 | 130 (29%) | 152 (43%) | <0.001 |
| Hyperlipidemia | 276 (37%) | 299 (35%) | 0.54 | 156 (34%) | 131 (37%) | 0.39 |
| Current smoking | 516 (69%) | 316 (37%) | <0.001 | 312 (67%) | 130 (37%) | <0.001 |
| Family history of CAD | 407 (54%) | 323 (38%) | <<0.001 | 248 (55%) | 148 (42%) | < 0.001 |
| Previous MI | 42 (6%) | 60 (7%) | 0.23 | 16 (4%) | 17 (5%) | 0.35 |
| Previous PCI | 47 (6%) | 48 (6%) | 0.62 | 19 (4%) | 17 (5%) | 0.66 |
| Anterior STEMI | 309 (41%) | 366 (43%) | 0.30 | 177 (39%) | 157 (45%) | 0.10 |
| Heart rate, beats per min* | 71 (59–84) | 71 (59–84) | 0.99 | 70 (59–84) | 71 (59–84) | 0.84 |
| Systolic BP, mmHg* | 131 (116–148) | 135 (120–154) | 0.23 | 131 (116–149) | 135 (120–154) | 0.062 |
| Diastolic BP, mmHg* | 80 (14) | 77 (15) | 0.015 | 80 (14) | 76 (15) | 0.005 |
| Symptom to balloon, min | 169 (124–267) | 182 (139–271) | 0.004 | 170 (124–271) | 181 (139–277) | 0.019 |
| ECG to first wire, min | 86 (68–115) | 84 (71–110) | 0.038 | 85 (69–114) | 85 (71–113) | 0.51 |
| Peak Troponin-T, ng/L | 2610 (954–5360) | 3290 (1455–6038) | <0.001 | 2825 (1052–5540) | 3360 (1620–6110) | <0.001 |
| Killip class ≥ 2 ** | 19 (3%) | 97 (11%) | <0.001 | 4 (1%) | 26 (7%) | <0.001 |
| Culprit lesion | 0.15 | 0.10 | ||||
| Left Main | 0 | 2 (0.2%) | 0 | 1 (0.3%) | ||
| LAD | 305 (40%) | 362 (43%) | 176 (39%) | 158 (45%) | ||
| RCA | 329 (44%) | 372 (44%) | 202 (44%) | 153 (43%) | ||
| LCX | 119 (16%) | 114 (13%) | 77 (17%) | 40 (11%) | ||
| TIMI flow 0/1 pre-PCI | 445 (59%) | 516 (61%) | 0.49 | 260 (57%) | 223 (63%) | 0.075 |
| Multivessel disease | 256 (34%) | 391 (46%) | <0.001 | 153 (34%) | 179 (51%) | <0.001 |
| TIMI flow 3 post-PCI | 731 (97%) | 804 (95%) | 0.014 | 446 (98%) | 336 (96%) | 0.037 |
| Medication at discharge | ||||||
| Aspirin | 744 (99%) | 826 (97%) | 0.022 | 452 (99%) | 342 (97%) | 0.015 |
| ADP inhibitor | 745 (99%) | 833 (98%) | 0.24 | 454 (99,8%) | 348 (99%) | 0.20 |
| Beta-blocker | 705 (94%) | 753 (89%) | <0.001 | 424 (93%) | 322 (91%) | 0.36 |
| ACEI / ARB | 285 (38%) | 405 (48%) | <0.001 | 169 (37%) | 165 (47%) | 0.005 |
Data are shown as mean (±SD), median (interquartile range) or numbers (%). Probabilities are for categorical variables derived from x2 and for continuous variables from Student’s t-test or Wilcoxon rank-sum test as appropriate.
ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin-II receptor blocker; ADP, adenosine diphosphate receptor; BMI, body mass index; CAD, coronary artery disease; CMR, cardiac magnetic resonance; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.*, at admission; **, during index hospitalization.